You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of mitoNEET agonists for the treatment of stroke

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Stroke is the fifth leading cause of death and the leading cause of disability in the United StatesThere remains a critical need for innovative therapeutic approaches that can successfully prevent or reverse brain injury following strokeDysfunction of the mitochondrial biochemistry following ischemic stroke and reperfusion injury contributes to significant neuronal cell losshoweverthe dev ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Novel Bio-Adhesive Mesh System for Abdominal Hernia Repair

    SBC: CIRCA BIOSCIENCE LLC            Topic: 300

    Development of a Novel Bio Adhesive Mesh System for Abdominal Hernia Repair Project Summary Abstract This project proposes the development of a novel mesh adhesive system for abdominal hernia repair utilizing surface modification of polymer surgical mesh to allow for improved tissue fixation with a poloxamine hydrogel adhesiveMore thanmillion Americans undergo hernia repair with surgical mesh each ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Developing and validating a podocyte cell-based diagnostic assay for identifying recurrent focal and segmental glomerulosclerosis patients

    SBC: InDepth Pharmaceuticals, LLC            Topic: 400

    Diagnosing glomerular diseases accurately and in timely fashion is key to developing a successful treatment plan and thereby prevent their progression to ESRDend stage renal diseaseHowevertheir successful diagnosis remains challenging due to the complex diagnostic procedures used including invasive renal biopsiesThusthere is a compelling need to develop simplified procedures to detect glomerular d ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Identifying hereditary cancer patients in low-resource community cancer settings using an innovative informatics solution

    SBC: SGgenomics, Inc.            Topic: 101

    PROJECT SUMMARYHereditary cancer risk assessment in low resource community cancer settings is a signi cant unmet clinical needUnfortunatelymost community cancer clinics do not have adequate access to genetics expertise and patients are not systematically assessed for hereditary riskNew cost e ective and practical approaches are needed to assess and identify patients at risk for hereditary cancer c ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted Chelation for Reversal of Vascular Calcification

    SBC: Elastrin Therapeutics Inc.            Topic: NHLBI

    PROJECT SUMMARY Medial arterial calcification is a form of vessel hardening in which calcium deposits are found in the medial layer of elastic and muscular arteriesspecifically on elastic fibersleading to arterial stiffening and tearingAn independent risk factor for cardiovascular diseases in diabetic and chronic kidney disease patientsit predisposes the patients to cardiovascular mortality and lo ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Next generation HDAC inhibitors with superior potency, selectivity, and pharmacokinetic profiles for the treatment of liver ischemia-reperfusion injury

    SBC: Lydex Pharmaceuticals LLC            Topic: 300

    Hepatic ischemia reperfusion injuryIRIoccurs in many clinical situationssuch as traumahepatic surgerye gliver resection for tumor treatmentliver donation and transplantationshock and vascular diseasesHepatic I R causes severe liver injury and promotes inflammationleading to liver dysfunctionmultiple organ failure and deathIt also compromises long term outcomes after surgery and traumaCurrentlyno e ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Development of the GlycoFibrotyper for detection of liver fibrosis

    SBC: GLYCOPATH INC            Topic: 300

    Increasinglyalterations in N linked glycans have been reported for serum or plasmaor for the most abundant serum glycoproteinimmunoglobulin Gfrom large cohorts of samples representing rheumatoid arthritisdigestive diseasescancer and liver fibrosisIn the case of fibrosistwo tests have identified alterations in Nlinked glycosylation on both total IgG populations and on specific IgG moleculesBoth of ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Aminoglycosides with reduced ototoxicity via miRNA targeting

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. We are developing fast and low cost methods to develop aminoglycosides with anti- ribosomal activities and reduced toxicity. In this project, we will identify novel aminoglycoside antibacterials, that show reduced o ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors

    SBC: Zylo Therapeutics Inc.            Topic: 400

    Radical prostatectomyRPis a commonly used treatment option for localized prostate cancerUnfortunatelythe procedure carries a risk of post surgical complications including a high risk of erectile dysfunctionEDThe main pathophysiological mechanism behind this is neuropraxia in which surgery either directly damages the cavernous nervesCNor does so indirectly through activation of an inflammatory resp ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government